1. Home
  2. BILL vs DNTH Comparison

BILL vs DNTH Comparison

Compare BILL & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BILL Holdings Inc.

BILL

BILL Holdings Inc.

HOLD

Current Price

$40.92

Market Cap

3.9B

Sector

Technology

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$86.31

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BILL
DNTH
Founded
2006
2015
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.6B
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
BILL
DNTH
Price
$40.92
$86.31
Analyst Decision
Buy
Strong Buy
Analyst Count
21
13
Target Price
$57.90
$121.00
AVG Volume (30 Days)
1.6M
492.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
74.07
N/A
EPS
0.07
N/A
Revenue
$1,462,570,000.00
$2,036,000.00
Revenue This Year
$14.18
N/A
Revenue Next Year
$13.83
$29.48
P/E Ratio
N/A
N/A
Revenue Growth
13.36
N/A
52 Week Low
$34.44
$16.77
52 Week High
$57.21
$96.50

Technical Indicators

Market Signals
Indicator
BILL
DNTH
Relative Strength Index (RSI) 58.57 50.54
Support Level $38.84 $82.00
Resistance Level $54.75 $88.45
Average True Range (ATR) 1.83 4.42
MACD 0.33 -0.90
Stochastic Oscillator 71.03 44.24

Price Performance

Historical Comparison
BILL
DNTH

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: